Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$62.63
neg -0.31
-0.49%
Today's Range: 62.58 - 63.00 | MRK Avg Daily Volume: 8,877,100
Last Update: 07/21/17 - 4:00 PM EDT
Volume: 6,898,870
YTD Performance: 6.39%
Open: $62.79
Previous Close: $62.94
52 Week Range: $57.18 - $66.80
Oustanding Shares: 2,735,164,510
Market Cap: 172,151,254,259
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 9
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.73 1.73 1.68
Latest Dividend: 0.47
Latest Dividend Yield: 2.99%
Dividend Ex-Date: 06/13/17
Price Earnings Ratio: 40.09
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
40.09 40.30 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.20% 6.53% 7.98%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.80 -0.10 -0.03
Net Income -11.60 -0.10 -0.04
EPS -9.60 -0.10 -0.02
Earnings for MRK:
EBITDA 11.47B
Revenue 39.81B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $0.87 $1.06 $3.85 $4.19
Number of Analysts 8 6 9 9
High Estimate $0.89 $1.09 $3.88 $4.41
Low Estimate $0.86 $1.01 $3.82 $4.10
Prior Year $0.93 $1.07 $3.78 $3.85
Growth Rate (Year over Year) -6.05% -0.93% 1.94% 8.85%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
MRK has shaped up on the charts.
It just isn't as useful or descriptive right now.

4 Undervalued Biotech Stocks Real Money Pro($)

Two are turnaround stories, and two are oversold.
Day 2 of the selloff brings in an entirely new kind of buyer.
The price momentum and money flow indicators of the drug maker are in positive alignment.
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly"
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
Biotech investors should keep a close eye on the progress in this huge potential market.
- Rev Shark, Yes, Market Lacks Fear, but There's No Emotion Either Several columns from me on the same theme today:   * I Fear the Absence of Fear of Loss  * More Wall Street Nonsense on Display  * Meshuganah Is Trump  * Thinking and Trading Opportunistically on the Short Side   Trade of the Week - Long a current fave - Allergan AGN!

Columnist Conversations

KMX is heading for a nice finish. The stock is up just over 2.7% and is one of the top ten gainers in the SP 5...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.